To provide for a limitation on availability of funds for Executive Office of the President, Office of National Drug Control Policy, Salaries and Expenses for fiscal year 2024.
Impact
The implications of HB2071 are significant as it tightens the financial resources allocated to the ONDCP, which is responsible for coordinating federal drug control efforts. By reducing funding, the bill suggests a reprioritization of how drug-related issues are managed at the federal level. This could impact various programs aimed at both prevention and enforcement concerning substance abuse and addiction, emphasizing a fiscal approach to drug control rather than an expansive one.
Summary
House Bill 2071 seeks to impose a cap on the availability of funds for the Executive Office of the President's Office of National Drug Control Policy (ONDCP) for the fiscal year 2024. The legislation explicitly limits the appropriated amounts to $18,400,000. This limitation is designed to ensure that national drug control policies function within stricter budgetary constraints, potentially reflecting broader priorities regarding federal spending in the context of drug control efforts.
Contention
Discussion surrounding HB2071 is likely to center on the adequacy of funding for drug control initiatives. Supporters may argue that the bill helps control government spending, while critics may contend that limiting financial resources could hinder effective drug policy implementation. There is an inherent tension between fiscal responsibility and the need for sufficient investment in public health and safety, particularly as numerous communities continue to grapple with the effects of substance abuse.
Notable_points
The proposal has drawn attention particularly from those who advocate for enhanced funding in national drug enforcement and treatment programs. The ONDCP plays a crucial role in addressing the opioid crisis and other drug-related issues facing the nation; thus, limitations on its funding could lead to increased scrutiny over how resources are allocated in response to ongoing drug epidemics. Stakeholders from both sides of the political spectrum will likely provide input on the implications of this bill's funding restrictions.
Close the Medigap Act of 2023 This bill (1) expands guaranteed issue rights with respect to Medigap policies (Medicare supplemental health insurance policies), (2) eliminates certain limitations on Medigap policies for newly eligible Medicare beneficiaries, and (3) modifies other provisions related to Medigap policies. (Guaranteed issue rights require that a policy be offered to any eligible applicant without regard to health status.)
World Deserves To Know Act This bill requires sanctions on certain members of the Chinese Communist Party (CCP) and officials of Chinese health agencies. It also addresses related issues. The President must impose visa- and property-blocking sanctions on any foreign person who is a CCP official and who is knowingly responsible for or complicit in (1) the disappearances of whistleblowers and citizen journalists in China relating to COVID-19, or (2) limiting free speech and academic freedom in China relating to COVID-19. The President must also impose such sanctions on specified individuals who have leadership positions in China's Center for Disease Control and Prevention and China's National Health Commission (NHC). The authority to impose such sanctions shall end when the President certifies to Congress that an independent and unimpeded investigation into the potential origin of COVID-19 from the Wuhan Institute of Virology has taken place. The bill also bars federal funds and certain federal student assistance from going to institutions of higher education that enter into a contract with any element or China-based affiliate of the NHC. Federal funding to the National Academy of Sciences may not be used to enter into a contract with any element or China-based affiliate of the NHC. The Government Accountability Office must report to Congress a review of all funds that the National Institutes of Health have made available to the NHC since FY2010. This report must also be publicly available.